
# SANTA CRUZ BIOTECHNOLOGY, INC.

# SPARC (AON-5031): sc-73472



#### BACKGROUND

SPARC (for secreted protein acidic and rich in cysteine) is a phosphorylated, acidic, glycine-rich glycoprotein that is secreted by endothelial cells and is present in large amounts in the parietal endoderm of mouse embryos and in human placenta. It is identical to osteonectin, a protein important to bone calcification that is highly conserved between species. SPARC, which can be selectively expressed by the endothelial cells *in vitro*. It regulates endothelial barrier function through F-Actin-dependent changes in cell shape, coincident with the appearance of intercellular gaps, which provide a paracellular pathway for extravasation of macromolecules.

#### **CHROMOSOMAL LOCATION**

Genetic locus: SPARC (human) mapping to 5q33.1; Sparc (mouse) mapping to 11 B1.3.

#### SOURCE

SPARC (AON-5031) is a mouse monoclonal antibody raised against SPARC of human origin.

# PRODUCT

Each vial contains 100  $\mu g$  lgG\_1 kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide, 0.1% gelatin and 5% glycerol.

# **APPLICATIONS**

SPARC (AON-5031) is recommended for detection of bone SPARC and platelet SPARC of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2  $\mu$ g per 100-500  $\mu$ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500).

SPARC (AON-5031) is also recommended for detection of bone SPARC and platelet SPARC in additional species, including bovine.

Suitable for use as control antibody for SPARC siRNA (h): sc-37166, SPARC siRNA (m): sc-41034, SPARC shRNA Plasmid (h): sc-37166-SH, SPARC shRNA Plasmid (m): sc-41034-SH, SPARC shRNA (h) Lentiviral Particles: sc-37166-V and SPARC shRNA (m) Lentiviral Particles: sc-41034-V.

Molecular Weight of SPARC: 43 kDa.

Positive Controls: SPARC (h): 293T Lysate: sc-111589, A-375 cell lysate: sc-3811 or U-2 OS cell lysate: sc-2295.

# **STORAGE**

Store at 4° C, \*\*D0 NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.


#### **PROTOCOLS**


See our web site at www.scbt.com for detailed protocols and support products.

#### **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

#### DATA





SPARC (AON-5031): sc-73472. Western blot analysis of SPARC expression in non-transfected: sc-117752 (**A**) and human SPARC transfected: sc-111589 (**B**) 293T whole cell lysates.

# SPARC (AON-5031): sc-73472. Western blot analysis of SPARC expression in A-375 whole cell lysate.

# SELECT PRODUCT CITATIONS

- Inoue, M., et al. 2010. Identification of SPARC as a candidate target antigen for immunotherapy of various cancers. Int. J. Cancer 127: 1393-1403.
- Rijkers, M., et al. 2017. Monitoring storage induced changes in the platelet proteome employing label free quantitative mass spectrometry. Sci. Rep. 7: 11045.
- Rijkers, M., et al. 2018. A subset of anti-HLA antibodies induces FcγRlladependent platelet activation. Haematologica 103: 1741-1752.
- 4. Jo, S., et al. 2020. DKK1 induced by 1,25D<sub>3</sub> is required for the mineralization of osteoblasts. Cells 9: 236.
- Rodrigues-Amorim, D., et al. 2021. Changes in the brain extracellular matrix composition in schizophrenia: a pathophysiological dysregulation and a potential therapeutic target. Cell. Mol. Neurobiol. 42: 1921-1932.
- Poomsawat, S., et al. 2021. Epithelial and fibroblast SPARC expression patterns in oral leukoplakia and oral squamous cell carcinoma. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 134: e44-e50.
- Ekici, O., et al. 2022. Kefir alters craniomandibular bone development in rats fed excess dose of high fructose corn syrup. J. Bone Miner. Metab. 40: 56-65.
- Alcaraz, L.B., et al. 2022. SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity. Int. J. Cancer 152: 1243-1258.
- Poomsawat, S., et al. 2024. Immunohistochemical expression of SPARC in odontogenic keratocysts: a comparative study with other odontogenic cysts. BMC Oral Health 24: 223.



See **SPARC (D-2): sc-398419** for SPARC antibody conjugates, including AC, HRP, FITC, PE, and Alexa Fluor<sup>®</sup> 488, 546, 594, 647, 680 and 790.